Sander Slootweg – Startup Investor Profile

Sander Slootweg is a seasoned investor and Managing Partner at Forbion. With a background in co-founding ABN AMRO Capital Life Sciences, Sander has established a remarkable track record in the investment field. He specializes in life sciences investments and has been instrumental in the success of Forbion since its inception in 2006. Sander’s investment focus areas include building companies at an earlier stage of development, as evidenced by his involvement in portfolio companies like Azafaros, NewAmsterdam Pharma, NorthSea Therapeutics, Oxyrane, and Replimune. His partnership and collaboration style are marked by a hands-on approach, serving on the boards of various companies to drive growth and success. Forbion’s recent fundraising success of â¬1.35 billion across two funds underscores Sander’s commitment to taking leading positions with investment sizes of up to â¬70 million per deal. Operating in the EU and NA regions, Sander Slootweg demonstrates a keen eye for transformative bio-pharmaceutical opportunities and a proactive investment strategy that positions him as a key player in the industry.

Location: Netherlands

Country: Netherlands

Investment Regions: EU, NA

Investment Stages: pre-seed, seed

Website: https://www.forbion.com/

AI Reasoning: I found a May 13, 2025 financing for Azafaros listing participation by Forbion (Forbion Growth and Forbion Ventures). While the Azafaros press release does not name Sander Slootweg specifically, Slootweg is a Managing Partner at Forbion and involved in Forbion investments; Forbion participated in May 2025 which is less than 6 months before the reference date, indicating recent activity. Additionally, Replimune board departure was July 20, 2023 (older), but the May 2025 Azafaros Series B with Forbion participation indicates investment activity within 6 months. The startup involved: Azafaros.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.